Virological and metabolic outcomes after switching to dolutegravir or rilpivirine in virologically suppressed adults with HIV in Thailand: an open-label, randomised, controlled, non-inferiority trial
Authors:
- Rattagan KajeekulRattagan Kajeekul
- Narisa RuenroengbunNRNarisa Ruenroengbun
- Sirichai WiwatrojanagulSWSirichai Wiwatrojanagul
- Kannarin KirdtongkumKKKannarin Kirdtongkum
- Walinda ChantaranothaiWCWalinda Chantaranothai
- Khairil Erwan Bin KhalidKKKhairil Erwan Bin Khalid
- Rujipas SirijatuphatRSRujipas Sirijatuphat
- Thundon NgamprasertchaiThundon Ngamprasertchai
Open Access
- 15 September 2026
- journal article
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 53
Abstract
No abstract availableFunding Information
- Royal College of Physicians of Thailand
- Faculty of Tropical Medicine, Mahidol University
- Mahidol University
This publication has 27 references indexed in Scilit:
- Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysiseClinicalMedicine, 2022
- Integrase Strand Transfer Inhibitors Are Associated With Incident Diabetes Mellitus in People With Human Immunodeficiency VirusClinical Infectious Diseases, 2022
- Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virusInternational Journal of Infectious Diseases, 2021
- Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical TrialsClinical Infectious Diseases, 2021
- Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor–Containing RegimensClinical Infectious Diseases, 2020
- Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countriesJournal of Antimicrobial Chemotherapy, 2018
- Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studiesThe Lancet, 2018
- Impact of Food and Different Meal Types on the Pharmacokinetics of RilpivirineThe Journal of Clinical Pharmacology, 2013
- Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialThe Lancet, 2011
- Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialThe Lancet, 2011